lead poisoning ( T56.0-) ICD-10-CM Diagnosis Code Z36.1 [convert to ICD-9-CM] Encounter for antenatal screening for raised alphafetoprotein level. Enctr for antenat screen for raised alphafetoprotein level; Encounter for antenatal screening for elevated maternal serum alphafetoprotein level. ICD-10-CM Diagnosis Code Z36.1.
Oct 01, 2021 · Z13.88 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Encntr screen for disorder due to exposure to contaminants. The 2022 edition of ICD-10 …
Encntr screen for disorder due to exposure to contaminants; Lead screening done; Screening for high lead level; those exposed to contaminants without suspected disorders (Z57.-, Z77.-) ICD-10-CM Diagnosis Code Z13.88
Oct 01, 2021 · Abnormal lead level in blood. 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code. R78.71 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R78.71 became effective on October 1, 2021.
The 2022 edition of ICD-10-CM Z13.88 became effective on October 1, 2021.
Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease. Type 1 Excludes. encounter for diagnostic examination-code to sign or symptom.
Abnormal lead level in blood 1 R78.71 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 The 2021 edition of ICD-10-CM R78.71 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of R78.71 - other international versions of ICD-10 R78.71 may differ.
The 2022 edition of ICD-10-CM R78.71 became effective on October 1, 2021.
mental or behavioral disorders due to psychoactive substance use ( F10-F19) Use Additional. code to identify the any retained foreign body, if applicable ( Z18.-) Findings of drugs and other substances, not normally found in blood.
The Centers for Disease Control and Prevention defines lead poisoning as a blood lead level of 10 mg/dL.
According to OSHA (1995), the blood lead level of all employees who are exposed to inorganic lead above 30 ug/m(3) for more than 30 days per year is to be determined at least every 6 months. The frequency is increased to every 2 months for employees whose last blood lead level was between 40 ug/100 g whole blood. For employees who are removed from exposure to lead due to an elevated blood lead, a new blood lead level must be measured monthly.
Kosnett et al (2007) summarized a body of published literature that establishes the potential for hypertension, effects on renal function, cognitive dysfunction, and adverse female reproductive outcome in adults with whole-blood lead concentrations less than 40 microg/dL. Based on this literature, and these researchers' collective experience in evaluating lead-exposed adults, they recommended that individuals be removed from occupational lead exposure if a single blood lead concentration exceeds 30 microg/dL or if 2 successive blood lead concentrations measured over a 4-week interval are greatet than or equal to 20 microg/dL. Removal of individuals from lead exposure should be considered to avoid long-term risk to health if exposure control measures over an extended period do not decrease blood lead concentrations to less than 10 microg/dL or if selected medical conditions exist that would increase the risk of continued exposure. Recommended medical surveillance for all lead-exposed workers should include quarterly blood lead measurements for individuals with blood lead concentrations between 10 and 19 microg/dL, and sem-iannual blood lead measurements when sustained blood lead concentrations are les than 10 microg/dL. It is advisable for pregnant women to avoid occupational or avocational lead exposure that would result in blood lead concentrations greater than 5 microg/dL. Chelation may have an adjunctive role in the medical management of highly exposed adults with symptomatic lead intoxication but is not recommended for asymptomatic individuals with low blood lead concentrations.
Aetna considers measurement of lead in bone, hair, teeth, or urine experimental and investigational because the effectiveness of these approaches has not been established.
Working with lead or living with someone who does—women who work in or who have family members who work in an industry that uses lead (e.g., lead production, battery manufacturing, paint manufacturing, ship building, ammunition production, or plastic manufacturing).
When lead-based paint peels and chips off of older walls, it can be inhaled and cause permanent damage to a young child's nervous system. Recurrent exposure to even small amounts of lead may result in lead poisoning since lead can accumulate in the body. Neurobehavioral abnormalities of mild lead poisoning may manifest as lowered IQ scores, decreased attention span, impaired hearing, speech and other developmental delays; however, most children of pre-school age with mild lead poisoning are asymptomatic. The probability of developing encephalopathy, the most serious complication of lead poisoning, increases as the exposure to lead and blood level of lead rises. Encephalopathy may be preceded by abdominal pain, headaches, vomiting, and constipation. The Centers for Disease Control and Prevention defines lead poisoning as a blood lead level of 10 mg/dL. As sustained blood levels rise above 10 to 15 mg/dL, young children under age 6 years are at progressively increasing risk not only for future neurobehavioral and cognitive problems, but also for development of recurrent symptomatic episodes of physical manifestations of lead poisoning.
Aetna considers blood lead testing (measurement of blood lead level) medically necessary for diagnosis of persons with signs and symptoms of lead poisoning (e.g., lowered IQ scores, decreased attention span, impaired hearing, speech and other developmental delays, abdominal pain, headaches, vomiting, and constipation).